SUMMARY One hundred and sixty nine patients (mean age 39 1 years) with documented dilated cardiomyopathy were studied for a mean of 5 5 years One hundred and four patients died during this period. The average (SD) interval from the onset of symptoms to death was 4 1 (3 7) years. One year and five year mortality rates were 27-8% and 57-4% respectively. Most of the deaths occurred within two years of diagnosis. The only difference between survivors and those who died was in the severity of left ventricular dysfunction at the time of referral. Significant differences between survivors and non-survivors were found for left ventricular end diastolic pressure (17-3 versus 23-4mmHg), left ventricular end systolic volume (87-4 versus 128 9 ml/m2), left ventricular end diastolic volume (130-7 versus 173-2 ml/m2), and ejection fraction (32-8 versus 25-4%). The duration of previous symptoms, preceding virus infection, positive family history, recent pregnancy, or heavy alcohol intake did not seem to influence prognosis. Nor did treatment, which was similar in both groups with a quarter of the patients receiving vasodilators.
Dilated cardiomyopathy is a heart muscle disease of unknown cause in which one or both ventricles are dilated and poorly contracting.' -3Various clinical, radiological, angiographic, haemodynamic, and histopathological variables have been suggested as predictors of outcome in dilated cardiomyopathy, but there is no uniform agreement about their usefulness. 46 One year mortality in this condition may vary from 31% to 35o%467 and five year mortality has been reported to be around 50%.7-' This poor prognosis seems not to have been modified during the past two decades, despite the introduction of new diuretics and the use of vasodilators and anticoagulants during this period.
To strengthen understanding of the clinical course of this disorder we report experience at Hammersmith Hospital in the diagnosis, treatment, and follow up of these patients. To our knowledge this is the largest series of patients with well documented dilated cardiomyopathy so far reported and the observations are relevant to the selection of patients
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Patients and methods
We retrospectively analysed data on 209 consecutive patients with dilated cardiomyopathy who were first seen in the Clinical Cardiology Unit (Department of Medicine) at Hammersmith Hospital from March 1962 to March 1982. Only 169 patients were included in the study. Eighteen patients were excluded because data were incomplete and twenty two were excluded because they had predominant or exclusive dilatation of the right ventricle. Most patients were referred for the evaluation of cardiac failure. All patients were followed up in the outpatient department. The follow up period was defined as the interval from the date of first admission to Hammersmith Hospital until either death or 31 March 1983. The interval from the onset of symptoms to the first admission was also analysed. 7 and the prognosis in this heart condition is one of the poorest. In the current series we observed a one year mortality of 27 8% and a five year mortality of over 50%. Most of our patients died within two years of the first evaluation at Hammersmith  Hospital (fig 1) . Conversely, patients who survived longer than this showed little tendency to die later. These were the patients who came to us despite not being on an obviously down-hill course. Their duration of symptoms before referral was similar to that in the patients who died. It is possible, indeed probable, that we are dealing with more than one disease process, but it is important to realise that a few patients with dilated cardiomyopathy can do well, with a good quality of life, and stable condition over many years even if they do not actually improve or "get better".
In All patients were on diuretics and all of those in atrial fibrillation were taking digoxin. One quarter of them were also taking vasodilator drugs. The efficacy of vasodilators in improving the haemodynamic state in these patients has already been proved26 27 but the improvement in measured exercise capacity is disappointing. Since vasodilators tended to be given to patients with worse left ventricular function (table 8) it was not possible to evaluate statistically the effect of these drugs on prognosis but there was certainly no obvious benefit in patients with advanced disease.
Despite two decades of hard investigation of dilated cardiomyopathy, the underlying cause or causes are still unknown and no treatment is yet available to reverse pathogenesis. Only an understanding of the underlying causes will make specific treatment possible. Improvement in the prognosis of these patients will only come when this knowledge is coupled with earlier recognition. We were unable to confirm from our data the suggestion that virus myocarditis had preceded or initiated dilated cardiomyopathy but we are perplexed by the great increase in biopsy diagnosis of myocarditis since 1982.
This is the largest series of patients with dilated cardiomyopathy so far reported. Its analysis confirmed that the disorder has a high mortality irrespective of the type of treatment, and the severity of left ventricular functional impairment (at referral) appears to be the main determinant of reduced survival, possibly because by the time symptoms develop or become at all limiting, dilatation may already have reached the point at which further deterioration is inevitable. Our observations are of importance in deciding the timing of cardiac transplantation. Some patients continue to do well and are stable for many years but patients with ejection fractions below 25% and deteriorating symptoms are unlikely to survive more than two years and may die at any time. 
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